EPISODE · May 26, 2025 · 14 MIN
Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study.YouTube: https://youtu.be/wJRlECiY2VAJoin us as we delve into:• The significance of MSI-high status in colorectal cancer and its prevalence.• The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates.• The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy.• Important side effects associated with the combination therapy and how to manage them.• Insights on patient selection for immunotherapy, including considerations for age and comorbidities.• The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer.Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment.Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025!#OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW
What this episode covers
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study.YouTube: https://youtu.be/wJRlECiY2VAJoin us as we delve into:• The significance of MSI-high status in colorectal cancer and its prevalence.• The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates.• The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy.• Important side effects associated with the combination therapy and how to manage them.• Insights on patient selection for immunotherapy, including considerations for age and comorbidities.• The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer.Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment.Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025!#OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW
NOW PLAYING
Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.